Vaxart settles proxy contest, adds activist-selected director and governance reforms

Filed July 2, 2026 · Period ending July 1, 2026 · ~1 min read

Key Changes

• high

  Vaxart resolved a proxy contest by agreeing to appoint a mutually-selected independent director within 60-90 days after the 2026 annual meeting, in exchange for the activist group withdrawing its three director nominations.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• medium

  The board will form two new committees—Clinical and Regulatory Affairs (chaired by James Breitmeyer) and Stockholder Engagement (chaired by the new director)—and adopt director stock ownership guidelines and a majority-vote resignation policy.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• medium

  Vaxart will reimburse the activist group up to $650,000 for proxy contest expenses and hold quarterly management meetings with the group through mid-2027 (extendable to mid-2028 if the new director is renominated).

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →